The American pharmaceutical group announces on Tuesday that it has earned in the first quarter revenues of 25.7 billion dollars, up sharply compared to the same period in 2021.
Tuesday, on Wall Street, the action of Pfizer fell 1.2% in electronic trading before the opening of the session.
AFP
The American pharmaceutical group Pfizer recorded sales of 25.7 billion dollars in the first quarter, up 77% year on year, largely thanks to sales of its vaccine once morest Covid-19, according to its results financials released on Tuesday. From January to March, the group’s net profit reached 7.9 billion dollars. Reported per share and excluding exceptional items, earnings were $1.62, above market forecasts.
Forecasts for annual turnover, on the other hand, are still between 98 and 102 billion dollars. The Cominarty vaccine once morest Covid-19 should represent sales of 32 billion dollars. “We continue to deliver Cominarty to the world, which remains a crucial tool in helping patients and societies avoid the worst effects of the Covid-19 pandemic,” Pfizer CEO Albert Bourla said in a statement. “We are on track to deliver on our commitment to deliver at least 2 billion pods to low- and middle-income countries in 2021 and 2022, including at least 1 billion this year,” added the leader.
The company has also maintained its forecast of selling $ 22 billion of its anti-Covid pill, Paxlovid, over the whole year. The World Health Organization strongly recommended in April this antiviral for patients with less severe forms of Covid-19 and “at higher risk of hospitalization”.
The group has ended clinical trials in Russia
Pfizer, on the other hand, revised its annual profit estimate downwards, mainly due to a change in its accounting standards. The American stock market regulator requires pharmaceutical groups to include certain expenses, in particular for acquisitions in research and development, in their financial projections. Pfizer now expects annual earnings per share to be between $6.25 and $6.45, down from a range of $6.35 to $6.55 previously.
On the Russian invasion of Ukraine, the group recalled that it had maintained its humanitarian deliveries of medicines to Russia, but that all the profits of its subsidiaries in the country were used to finance humanitarian aid for the people. Ukrainian. Pfizer has also indicated that it will no longer initiate clinical trials in Russia, no longer recruit new patients for ongoing clinical trials and suspend future investments in local partners for the construction of factories.
(AFP)
